Trial Profile
A phase III, Randomized, two armed, parallel, double blind Controlled non inferiority clinical Trial of Tinapeg(Produced by AryaTinaGene.) versus Neulastim for Preventing Chemotherapy induced Febrile Neutropenia in breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2018
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Chemotherapy induced febrile neutropenia
- Focus Registrational; Therapeutic Use
- Sponsors AryaTinaGene Biopharmaceuticals
- 22 Feb 2018 Status changed from recruiting to completed.
- 22 Dec 2017 New trial record